CLINICAL TRIALS PROFILE FOR ZANTAC IN PLASTIC CONTAINER

505(b)(2) Clinical Trials for ZANTAC IN PLASTIC CONTAINER

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT00443963 ↗	Total Antioxidant Effects of Esomeprazole in Dyspeptic Patients Receiving Non-steroidal Anti-inflammatory Drugs	Withdrawn	AstraZeneca	Phase 4	2006-12-01	The principal investigator hypothesizes that participants receiving NSAID drugs with dyspeptic symptoms have increased production of gastric levels of free radicals. The primary objective of the study is to determine if Esomeprazole Magnesium increases gastric total antioxidant capacity and decreases gastric free radical production in humans. Participants (age 18 years and older) with no history of upper GI bleeding who are receiving non-steroidal anti-inflammatory drugs and then develop dyspepsia will be recruited from our primary care clinic in Washington, DC. All eligible participants will undergo biopsies of antrum and corpus. The participants will be randomized to receive either Zantac OTC or Nexium for 15 days. On day 15, all participants will undergo repeat upper endoscopy to obtain biopsies of antrum and corpus. Tissue samples will then be extracted to determine total antioxidant capacity and lipid peroxide levels (as an indirect marker of free radical production).
OTC	NCT00443963 ↗	Total Antioxidant Effects of Esomeprazole in Dyspeptic Patients Receiving Non-steroidal Anti-inflammatory Drugs	Withdrawn	Medstar Health Research Institute	Phase 4	2006-12-01	The principal investigator hypothesizes that participants receiving NSAID drugs with dyspeptic symptoms have increased production of gastric levels of free radicals. The primary objective of the study is to determine if Esomeprazole Magnesium increases gastric total antioxidant capacity and decreases gastric free radical production in humans. Participants (age 18 years and older) with no history of upper GI bleeding who are receiving non-steroidal anti-inflammatory drugs and then develop dyspepsia will be recruited from our primary care clinic in Washington, DC. All eligible participants will undergo biopsies of antrum and corpus. The participants will be randomized to receive either Zantac OTC or Nexium for 15 days. On day 15, all participants will undergo repeat upper endoscopy to obtain biopsies of antrum and corpus. Tissue samples will then be extracted to determine total antioxidant capacity and lipid peroxide levels (as an indirect marker of free radical production).
OTC	NCT03145012 ↗	Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity	Unknown status	Dalhousie University	Phase 4	2018-05-01	The immune response against tumors can be highly effective in preventing tumor development, growth and metastasis under certain circumstances. However, tumor associated immune suppression can profoundly limit the impact of natural tumor immunity and also reduce the effectiveness of tumor immunotherapy strategies. A major component of tumor associated immune suppression is mediated by myeloid cells, especially the monocytic subset of myeloid derived suppressor cells (MDSC). In recent studies that were conducted through a CCSRI Innovation grant, the investigators discovered that oral treatment of mice with the commonly used histamine receptor 2 (H2) antagonists ranitidine or famotidine inhibits both primary breast tumor development and metastasis, in three distinct mouse tumor models and reduces the numbers of monocytic MDSC. These findings have enormous potential to aid in effective cancer immunotherapy and may have immediate implications for cancer patients. The objective of this investigation is to determine whether treatment with the H2 receptor antagonist ranitidine alters immune suppression, through modulation of immune cell populations. The investigators will examine peripheral blood monocyte, neutrophil and NK cell numbers, subsets and activation status from healthy volunteers treated for 6 weeks with daily oral ranitidine. Ranitidine is widely available and used over the counter in Canada. These drugs are widely recognized as safe, well tolerated and have very few side effects. It has been suggested that among the general population, over 10% of those over the age of 65 take such medications on a regular basis for relief against gastrointestinal discomfort. The outcome of pre-clinical studies in mice warrant further investigation into transferability to humans. If the outcome of the current proposal proves to be viable, then these drugs could provide a safe method to reduce tumor associated immunosuppression with broad implications, both for current cancer patients and for those at high risk of developing cancer. Further to this, the outcome of our proposal may provide a new strategy for improving the effectiveness of T-cell mediated immunotherapy.

All Clinical Trials for ZANTAC IN PLASTIC CONTAINER

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00030992 ↗	BMS 247550 to Treat Kidney Cancer	Completed	National Cancer Institute (NCI)	Phase 2	2002-02-01	This study will examine whether the experimental drug BMS 247550 (Ixabepilone) is an effective treatment for kidney cancer. BMS 247550 belongs to a class of drugs called epothilones that interfere with the ability of cancer cells to divide. In the way they kill cells, they are very similar to a class of compounds known as the taxanes, which include the drug Taxol. Other characteristics of the epothilones, however, enable them to work in cells that are resistant to Taxol. Patients 18 years of age or older with kidney cancer that has not spread to the central nervous system (unless the brain tumor has remained stable for at least six months after surgical or radiation treatment) may be eligible for this study. Pregnant or nursing women may not participate. Candidates are screened with various tests that may include blood and urine tests, electrocardiogram (EKG), and chest x-ray. Computerized tomography (CT) scans or X-rays, and possibly nuclear medicine studies may be done to determine the extent of disease. Participants receive BMS 247550 by a 1-hour infusion into a vein for 5 consecutive days (days 1, 2, 3, 4 and 5) of each 21-day treatment cycle. Patients must stay in the National Institutes of Health (NIH) area near Bethesda, Maryland, for 7 to 8 days during the first treatment cycle and for the 5 days of treatment in subsequent cycles. The total number of cycles will vary among patients, depending on their individual clinical situation. The drug dose may be increased gradually in subsequent cycles in patients who can tolerate such increases. In addition, participants undergo the following tests and procedures: - Periodic physical examinations and frequent blood tests - X-ray and other imaging studies to determine if the tumor is responding to the treatment. - Tumor biopsies to confirm the diagnosis or spread of tumor and to examine the reaction of certain proteins in cancer cells to BMS 247550. Two biopsies will be done. For this procedure, a small piece of tumor tissue is withdrawn through a needle under local anesthetic. Treatment will be stopped in patients whose tumor grows while receiving BMS 247550. Patients whose tumor disappears completely will be followed at NIH periodically for examinations and tests. Patients whose disease does not completely resolve or whose disease recurs may be advised of other appropriate research protocols at NIH or, if none are available, will be returned to the care of their local doctor.
NCT00223691 ↗	Treatment of Orthostatic Hypotension in Autonomic Failure	Completed	Vanderbilt University	Phase 1	2002-03-01	The autonomic nervous system serves multiple regulatory functions in the body, including the regulation of blood pressure and heart rate, gut motility, sweating and sexual function. There are several diseases characterized by abnormal function of the autonomic nervous system. Medications can also alter autonomic function. Impairment of the autonomic nervous system by diseases or drugs may lead to several symptoms, including blood pressure problems (e.g., high blood pressure lying down and low blood pressure on standing), sweating abnormalities, constipation or diarrhea and sexual dysfunction. Because treatment options for these patients are limited. We propose to study patients autonomic failure and low blood pressure upon standing and determine the cause of their disease by history and examination and their response to autonomic testing which have already been standardized in our laboratory. Based on their possible cause, we will tests different medications that may alleviate their symptoms.
NCT00223691 ↗	Treatment of Orthostatic Hypotension in Autonomic Failure	Completed	Vanderbilt University Medical Center	Phase 1	2002-03-01	The autonomic nervous system serves multiple regulatory functions in the body, including the regulation of blood pressure and heart rate, gut motility, sweating and sexual function. There are several diseases characterized by abnormal function of the autonomic nervous system. Medications can also alter autonomic function. Impairment of the autonomic nervous system by diseases or drugs may lead to several symptoms, including blood pressure problems (e.g., high blood pressure lying down and low blood pressure on standing), sweating abnormalities, constipation or diarrhea and sexual dysfunction. Because treatment options for these patients are limited. We propose to study patients autonomic failure and low blood pressure upon standing and determine the cause of their disease by history and examination and their response to autonomic testing which have already been standardized in our laboratory. Based on their possible cause, we will tests different medications that may alleviate their symptoms.

Clinical Trial Conditions for ZANTAC IN PLASTIC CONTAINER

Condition Name

Condition Name for ZANTAC IN PLASTIC CONTAINER
Intervention	Trials
Healthy	2
NSAID Associated Gastric Ulcers	2
Barrett Esophagus	1

Condition MeSH

Condition MeSH for ZANTAC IN PLASTIC CONTAINER
Intervention	Trials
Ulcer	3
Stomach Ulcer	2
Hypotension	2

Clinical Trial Locations for ZANTAC IN PLASTIC CONTAINER

Trials by Country

Trials by Country for ZANTAC IN PLASTIC CONTAINER
Location	Trials
United States	12
Canada	2
Pakistan	2
United Kingdom	1
Egypt	1

Trials by US State

Trials by US State for ZANTAC IN PLASTIC CONTAINER
Location	Trials
Maryland	3
Texas	2
Massachusetts	1
District of Columbia	1
New York	1

Clinical Trial Progress for ZANTAC IN PLASTIC CONTAINER

Clinical Trial Phase

Clinical Trial Phase for ZANTAC IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Phase 4	5
Phase 3	3
Phase 2	6

Clinical Trial Status

Clinical Trial Status for ZANTAC IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Completed	13
Withdrawn	4
Terminated	2

Clinical Trial Sponsors for ZANTAC IN PLASTIC CONTAINER

Sponsor Name

Sponsor Name for ZANTAC IN PLASTIC CONTAINER
Sponsor	Trials
National Cancer Institute (NCI)	3
AstraZeneca	3
M.D. Anderson Cancer Center	2

Sponsor Type

Sponsor Type for ZANTAC IN PLASTIC CONTAINER
Sponsor	Trials
Other	18
Industry	7
NIH	4

ZANTAC IN PLASTIC CONTAINER Market Analysis and Financial Projection

Last updated: May 3, 2026

What is the clinical and market outlook for “Zantac in plastic container” (ranitidine), and how does the patent landscape shape projections?

Zantac (ranitidine) is a reformulated, branded H2-receptor antagonist that was widely commercialized before global safety actions against ranitidine. Current commercialization status, regulatory outcomes, and the absence of enforceable, active brand-based exclusivity materially cap near- to medium-term revenue projections tied to the “Zantac” brand in any specific container format.

Across major markets, ranitidine’s market availability and sponsor activity have been constrained by regulatory actions tied to NDMA (N-nitrosodimethylamine) impurity risk, including withdrawals and restrictions. These actions drive the practical market outlook more than container design.

What happened to ranitidine (Zantac) after NDMA-linked safety actions?

Regulatory outcomes tightened rapidly, affecting manufacturing, distribution, and prescribing:

• United States (FDA): In April 2020, FDA requested withdrawal of all ranitidine products from the market due to unacceptable NDMA levels under certain conditions. FDA described NDMA formation increasing over time at room temperature. (FDA, 2020)
• Europe (EMA and national agencies): Multiple EU regulators restricted ranitidine-containing products and proceeded toward withdrawal aligned to NDMA risk. (EMA, 2020)
• Global impact: Suppliers shifted away from ranitidine; the brand’s re-entry paths became limited by safety and impurity controls, plus consumer and prescriber confidence.

These actions effectively make “Zantac in plastic container” a historical product form rather than a current growth vector. The container type does not change the underlying NDMA risk profile that regulators targeted.

---

Clinical trials: What is the current state of ranitidine trial activity?

Ranitidine trials largely transitioned from classic H2-antagonist indications to either:

1. historical effectiveness evidence, and
2. limited exploratory work (often not aimed at re-establishing “Zantac” as a live commercial pipeline).

Because the drug’s commercialization is constrained by regulatory safety decisions, the practical trial relevance for market projections is low: new trials do not automatically reopen approval if the safety issue remains unresolved and regulator-recognized.

Implication for projections: Even where academic or legacy registry records exist, they do not translate into near-term market expansion for “Zantac” as a brand product.

---

Market analysis: What does the NDMA-driven regulatory reset imply for “Zantac in plastic container”?

How do container claims factor into market demand?

A container change can influence stability and shelf-life, but regulators explicitly focused on NDMA formation under certain storage conditions. FDA’s reasoning centered on NDMA formation and unacceptable impurity levels, not packaging marketing. (FDA, 2020)

So “in plastic container” does not function as a credible differentiator for:

• regulatory acceptance,
• prescriber confidence, or
• insurer and pharmacy stocking decisions,

when the active ingredient remains associated with the impurity risk.

What is the feasible revenue path under current realities?

For a brand tied to ranitidine, the market path typically falls into one of two buckets:

• No meaningful retail re-expansion: product withdrawals and replacement by other H2 blockers or proton pump inhibitors (PPIs) reduce the addressable market for “Zantac.”
• Niche or limited re-launch only where regulators permit and sponsors meet impurity controls: even then, it depends on active approvals in each country and the absence of NDMA concerns under defined handling and storage.

In practice, “Zantac in plastic container” is not a standalone commercialization thesis. It is a formatting descriptor for a product whose active ingredient faced global discontinuation pressure. (FDA, 2020; EMA, 2020)

---

Patent and exclusivity: Does container format carry enforceable IP leverage?

For “Zantac in plastic container,” the actionable IP question is whether any rights still exist that would block generic ranitidine or enable sustained branded differentiation. The answer hinges on:

• Active ingredient patent term: ranitidine is an older molecule, so composition-of-matter protection is largely long expired.
• Brand exclusivity: when availability was revoked or effectively ended, brand exclusivity does not create a re-entry market without regulator approval.
• Packaging patents: even if packaging innovations exist, packaging IP rarely restores market viability when regulators have targeted impurity risk of the active ingredient.

Practical read-through for investors: the dominant constraint is regulatory status, not residual exclusivity. Any projection that assumes “Zantac” brand retention based on packaging is not consistent with the NDMA actions.

---

Market projection: What timeline and magnitude are realistic?

Base case (most plausible): continued contraction and minimal re-growth

Given the FDA withdrawal request and EU restrictions tied to NDMA, the base case is:

• No material growth for “Zantac” packaging formats
• Limited market role for ranitidine as a class relative to alternatives (PPIs and other H2 blockers not implicated by the same NDMA risk outcomes)

FDA’s request to withdraw all ranitidine products in the US is a major demand-destroyer and distributor behavior shock. (FDA, 2020)

Upside case: only if a regulator-recognized reformulation re-enters

An upside scenario requires:

• regulator-permitted ranitidine products under updated impurity controls and stability protocols, and
• pharmacy and prescriber willingness to resume stocking.

This is not a container-driven upside. It is a manufacturing and regulatory compliance-driven path. (FDA, 2020)

Downside case: further tightening or continued scarcity

A downside scenario is continued low availability and further market shrinkage driven by:

• additional impurity findings in storage conditions,
• tightened monograph interpretations, or
• ongoing manufacturer discontinuation.

---

Actionable business implications

If you are planning R&D investment

• Treat ranitidine re-commercialization as a regulatory reinstatement problem, not a packaging problem.
• Allocate screening resources to alternatives with better current regulatory standing, or to new chemical entities with clear IP and impurity pathways.

If you are assessing licensing or business development

• Any deal framed on “Zantac in plastic container” is a low-confidence thesis unless it is anchored to:
  • live regulatory approvals in target countries,
  • validated impurity and NDMA control evidence,
  • and active supply.

---

Key Takeaways

• FDA requested withdrawal of all ranitidine products in 2020 due to unacceptable NDMA levels and NDMA formation under storage conditions. (FDA, 2020)
• EMA and EU regulators implemented restrictions aligned to NDMA risk, reinforcing market exit dynamics. (EMA, 2020)
• “Zantac in plastic container” does not overcome the core impurity and regulatory basis for withdrawal; container format does not drive legal or commercial viability by itself.
• Patent leverage for packaging alone is unlikely to restore the market for a withdrawn active ingredient; feasible projections are capped by regulatory status.

---

FAQs

1) Is Zantac (ranitidine) currently available in the US?

FDA requested withdrawal of all ranitidine products from the market in 2020 due to NDMA impurity concerns. (FDA, 2020)

2) Does plastic packaging reduce NDMA and change the regulatory outcome?

Regulatory action focused on NDMA formation and unacceptable impurity levels in ranitidine products under certain conditions; container type is not an approval pathway by itself. (FDA, 2020)

3) Are there new clinical trials that would restore Zantac sales?

The practical commercial question is regulatory reinstatement. Historical or limited trial activity does not automatically reverse the NDMA-driven withdrawal basis. (FDA, 2020; EMA, 2020)

4) Is there still meaningful brand exclusivity for “Zantac” in any market?

For ranitidine, active ingredient patent protection is long past. Brand exclusivity does not create availability without regulatory clearance and compliant supply. (FDA, 2020)

5) What is the most realistic market projection for “Zantac in plastic container”?

A continued constrained role with no material re-growth unless regulators permit a compliant ranitidine product and manufacturers re-enter markets under validated impurity controls. (FDA, 2020; EMA, 2020)

---

References (APA)

1. U.S. Food and Drug Administration. (2020, April). FDA requests removal of all ranitidine products (Zantac) from the market. https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market
2. European Medicines Agency. (2020). PRAC recommendations on signals: Ranitidine and NDMA. https://www.ema.europa.eu/en/documents/referral/ranitidine-article-31-referral-prac-assessment-report_en.pdf